ECCN European Conference on Clinical Neuroimaging - Brussels Belgium 2018

INVITED SPEAKERS 2019 AND THEIR PRESENTATION



SIMON CERVENKA

May 21, 9.10 - 9.40am - "Is synaptic density altered in psychiatric diseases?"

In recent years multiple lines of research has suggested an involvement of the immune system in psychiatric disorders. In schizophrenia, recent observations highlight a role for microglia in overactive pruning. Dr Cervenka will summarize the evidence for immune-related synaptopathy in schizophrenia, and how we can target these processes using molecular imaging.
 

ANDREAS JACOBS

May 20, 2.00 - 2.45pm - "Novel PET tracers: from target identification to clinical applications." 
 
Novel PET tracers: from target identification to clinical application
The lecture will cover the (reverse-)translational research activities of the INMIND consortium (2012-2018) in the attempts to image disease-driving microglia activation based on “novel” radiotracers targeting TSPO as well as alternative microglial targets.

PHILIPPE LAMBIN

May 21, 11.40am - 12.10pm - "Radiomics: Medical images are not pictures, they are data. Potential application in neuroconcology"
 
Radiomics, the high-throughput mining of quantitative image features from standard-of-care medical imaging that enables data to be extracted and applied within clinical-decision support systems to improve diagnostic, prognostic, and predictive accuracy, is gaining importance in cancer research and has multiple applications in neuro-imaging.
Radiomics, the high-throughput mining of quantitative image features from standard-of-care medical imaging that enables data to be extracted and applied within clinical-decision support systems to improve diagnostic, prognostic, and predictive accuracy, is gaining importance in cancer research and has multiple applications in neuro-imaging.

 

ADRIAAN LAMMERTSMA

May 20, 2.45 - 3.30pm - "Opportunities and pitfalls in quantifying neuroinflammation using PET" 
 
Neuroinflammation is associated with microglia activation. This, in turn, results in increased TSPO expression, which can be imaged by TSPO PET tracers. Quantification of TSPO expression, however, has proven to be difficult due to the low signal to noise ratios obtained with first generation TSPO tracers. Although some second generation TSPO tracers provide higher signal to noise ratios, quantification remains difficult partly because polymorphism. This presentation will provide an overview of efforts to quantify uptake of TSPO ligands, which is possible provided sufficient detail is given to experimental design. In addition, other future prospect of novel non-TSPO ligands associated with neuroinflammation will be discussed.

 

ANDREAS VARRONE

May 21, 8.40 - 9.10am - "Synaptic density in neurodegenerative diseases."

Andrea Varrone, MD, PhD, Associate Professor of Nuclear Medicine at the Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. He is research group leader for Molecular brain imaging of neurodegenerative disorders. The focus of his research is the development of PET imaging markers for the study of Parkinson´s disease and dementia. In his talk he will provide an overview on imaging of SV2A in neurodegenerative disorders. 

GIOVANNI FRISONI

May 20, 9.30 - 10.15Am - "Present and future of molecular imaging in the clinic" 

               Share Share

News | general information | Archives | Press Presse | Newsletters | DOCUMENTS